Levodopa‐carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation

A new levodopa‐carbidopa intestinal gel (LCIG) system featuring a higher levodopa/carbidopa (LD/CD) concentration and viscosity, LCIG‐HV, is being developed to reduce the intrajejunal volume of LD/CD that is administered as compared to the current commercial formulation, LCIG‐LV. This study characte...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosebraugh, Matthew, Kalluri, Hari V., Liu, Wei, Locke, Charles, Sidhu, Dilraj, Han, Jian‐Hwa, Benesh, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452870/
https://www.ncbi.nlm.nih.gov/pubmed/30977301
http://dx.doi.org/10.1002/prp2.473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452870/
https://www.ncbi.nlm.nih.gov/pubmed/30977301
http://dx.doi.org/10.1002/prp2.473

Ejemplares similares